Page 345 - 2022_01-Haematologica-web

Letters to the Editor
doi:10.3324/haematol.2020.263715 Received: June 18, 2020.
Accepted: October 7, 2021. Pre-published: October 14, 2021.
Disclosures: GMR received honoraria from Abbvie, Gilead and Janssen and research funding from Gilead; AC received honoraria from Abbvie, Gilead, Janssen, and is part of the advisory board/speakers bureau of AstraZeneca; RF received honoraria from Abbvie, Janssen, Shire/Takeda, is part of the advisory board/speakers bureau of Gilead; IDG received honoraria from Toledo and is part
of the advisory board of AstraZeneca.
Contributions: LC performed NGS experiments, the bioinformatic analysis and wrote the manuscript; SR performed NGS experiments and wrote the manuscript; LVC performed NGS experiments and contributed to the results’ analysis; CI performed and analyzed Sanger sequencing; RS performed NGS experiments; MSDP performed flow cytometry; PM and NP managed samples collection/processing and the biologic database; GMR and AB performed karyotype analysis; AP and VA performed the statistical analysis; FRM led the clinical trial and managed patients; AC, AG and RF discussed the results and critically revised the manuscript; IDG designed and supervised the study and wrote the manuscript.
Funding: the authors wish to thank the Associazione Italiana per la Ricerca sul Cancro (AIRC), Metastases Special Program, N° 21198, Milan, Italy (RF); Progetti di Rilevante Interesse Nazionale (PRIN) 2015ZMRFEA (RF, AC).
References
1. O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treat- ment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5- year experience. Blood. 2018;131(17):1910-1919.
2. Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up
to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353-1363.
3. Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first- line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787-798.
4. Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S- mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017; 35(13):1437-1443.
5.Burger JA, Landau DA, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat. Commun. 2016;7:11589.
6. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibru- tinib resistance in chronic lymphocytic leukemia. Blood. 2017; 129(11):1469-1479.
7. Landau DA, Sun C, Rosebrock D, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8(1):2185.
8. Kanagal-Shamanna R, Jain P, Patel KP, et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lympho- cytic leukemia with disease progression and Richter transformation. Cancer. 2019;125(4):559-574.
9. Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123(14):2139-2147.
10. Malcikova J, Stano-Kozubik K, Tichy B, et al. Detailed analysis of thera- py-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia. 2015;29(4):877-885.
11. Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lympho- cytic leukemia. Blood. 2016;127(17):2122-2130.
12. Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib- relapsed CLL. Blood Adv. 2017;1(12):715-727.
13. Gángó A, Alpár D, Galik B, et al. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer. 2020;146(1):85-93.
14. Malcikova J, Pavlova S, Kunt Vonkova B, et al. Low-burden TP53 muta- tions in CLL: Clinical impact and clonal evolution within the context of different treatment options. Blood. 2021 May 4. [Epub ahead of print]
15. Guarini A, Peragine N, Messina M, et al. Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib. Br J Haematol. 2019;184(3):392-396.
haematologica | 2022; 107(1)
337